ArticleJournal of the International AIDS Society2025
High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir-lamivudine-dolutegravir: a prospective cohort study.
Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multiomic investigation of human milk-derived extracellular vesicles in perinatal HIV and antiretroviral therapy exposure.Molecular medicine (Cambridge, Mass.) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAchieving and maintaining viral suppression (VS) during pregnancy and breastfeeding is central to preventing vertical transmission and optimizing maternal health. High rates of VS have been demonstrated among adult and paediatric populations receiving tenofovir-lamivudine-dolutegravir (TLD), but VS and viraemia among pregnant and postpartum women with HIV (WHIV) in high-burden settings have not been well-documented.
methodsBetween September 2021 and December 2023, pregnant WHIV, ≤18 weeks gestation, were enrolled in antenatal care (ANC) and followed postpartum in Cape Town, South Africa. WHIV received HIV care in routine health services and continued, switched to or initiated TLD at ANC entry. VS was defined as viral load (VL) <50 copies/ml; viraemic episodes (VEs) were categorized as major (>1000 copies/ml) or minor (50-1000 copies/ml). Mixed-effects Poisson regression models were fit to assess factors associated with major VE risk.
resultsAmong 763 WHIV with ≥1 VL, median age was 30 years (interquartile range [IQR] 25-34) and median gestation was 14 weeks at enrolment (IQR 11-17); 89% were on antiretroviral therapy, including 74% on TLD. Overall 99% achieved ≥1 VL<50 copies/ml: 73% sustained VS through 48 weeks postpartum, with 16% having ≥1 minor VE and 15% ≥1 major VE. At enrolment, 77% of VL measures were <50 copies/ml, increasing to >90% during pregnancy through 12 weeks postpartum and declining to 81% by 24 weeks postpartum. In multivariable analysis, each additional year of age conferred a 6% (95% confidence interval [CI] 0.89, 0.98, p = 0.006) lower risk of subsequent major VE after achieving VS. WHIV with viraemia (50-1000 copies/ml) at enrolment were 3.6 (95% CI 1.94, 6.70, p<0.001) times more likely to have a subsequent major VE, whereas CD4+>500 cells/mm lowered major VE risk by 53% (95% CI 0.32, 0.89, p = 0.016).
conclusionsHigh rates of VS were maintained during pregnancy and early postpartum, but substantial viraemia emerged by 24 weeks postpartum, jeopardizing maternal and child health outcomes. These unique data provide further impetus to explore innovative approaches to supporting adherence among WHIV during the postpartum period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.